HSNOHbio focuses on the intersection of molecular neuroscience, computational chemistry, and precision pharmacology.
Our research investigates whether selective allosteric modulation of the GluA3 AMPA receptor can provide new opportunities for CNS therapeutic development.
AMPA receptors are central components of excitatory neurotransmission and play important roles in synaptic plasticity and cognitive function.
The GluA3 receptor subtype presents structural features that may offer opportunities for subtype-selective molecular intervention.
Our lead candidate, G3-01EG, was developed through computational molecular design to explore potential interactions with a GluA3-associated allosteric region.
1. Molecular Binding Validation
Evaluate compound binding and compare receptor subtype selectivity using appropriate biophysical assays.
2. Electrophysiological Characterization
Investigate functional effects on AMPA receptor activity using patch-clamp electrophysiology.
3. Binding-Site Confirmation
Explore the proposed molecular interaction mechanism through targeted receptor mutagenesis, including investigation of Arg163.
4. Pharmacokinetic Evaluation
Assess drug-like properties, metabolic stability, and potential central nervous system exposure.
5. Preclinical Efficacy and Safety
Evaluate biological effects and safety profiles in appropriate experimental models following successful initial validation.
Our approach combines computational innovation with rigorous experimental validation to translate molecular hypotheses into scientifically supported therapeutic opportunities.